H.B. No. 3057 amends the Texas Insurance Code by adding a new Subchapter E-2, which mandates health benefit plans to provide coverage for chimeric antigen receptor T-cell therapy. This coverage applies to various types of health benefit plans, including individual and group insurance policies, hospital service contracts, and health maintenance organizations. The bill specifies that the therapy must be deemed medically necessary and administered by a qualified healthcare provider that is certified and part of the health benefit plan's network.

The bill also outlines exceptions to its applicability, stating that it does not apply to issuers or providers under the state Medicaid program or the child health plan program. Additionally, the Texas Insurance Commissioner is tasked with adopting necessary rules to administer this subchapter. The provisions of this act will take effect on September 1, 2025, and will apply to health benefit plans delivered, issued for delivery, or renewed on or after January 1, 2026.

Statutes affected:
Introduced: ()
House Committee Report: ()
Engrossed: ()
Senate Committee Report: ()
Enrolled: ()